Media stories about CymaBay Therapeutics (NASDAQ:CBAY) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. CymaBay Therapeutics earned a media sentiment score of 0.07 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 47.1478698252233 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the news headlines that may have effected Accern Sentiment’s analysis:
- Brokers Issue Forecasts for CymaBay Therapeutics Inc.’s FY2017 Earnings (CBAY) (americanbankingnews.com)
- CymaBay Therapeutics Inc. (CBAY) Sees Large Growth in Short Interest (americanbankingnews.com)
- Leerink Swann Comments on CymaBay Therapeutics Inc.’s Q1 2018 Earnings (CBAY) (americanbankingnews.com)
- CymaBay Reports Third Quarter 2017 Financial Results and Corporate Updates – GlobeNewswire (press release) (globenewswire.com)
- CymaBay Therapeutics’ (CBAY) CEO Sujal Shah on Q3 2017 Results – Earnings Call Transcript – Seeking Alpha (seekingalpha.com)
CymaBay Therapeutics (NASDAQ CBAY) traded up $0.56 during mid-day trading on Monday, reaching $9.25. The company’s stock had a trading volume of 755,000 shares, compared to its average volume of 734,731. The company has a current ratio of 7.39, a quick ratio of 7.39 and a debt-to-equity ratio of 0.04. CymaBay Therapeutics has a 1 year low of $1.46 and a 1 year high of $9.40.
CymaBay Therapeutics (NASDAQ:CBAY) last posted its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.02). During the same period in the previous year, the company posted ($0.25) earnings per share. equities analysts expect that CymaBay Therapeutics will post -0.83 EPS for the current fiscal year.
CBAY has been the topic of a number of research analyst reports. Cantor Fitzgerald initiated coverage on CymaBay Therapeutics in a research note on Tuesday, September 19th. They issued an “overweight” rating and a $16.00 price target on the stock. Zacks Investment Research upgraded CymaBay Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, September 18th. Piper Jaffray Companies restated a “buy” rating and issued a $12.00 price target on shares of CymaBay Therapeutics in a research note on Friday, October 27th. Ifs Securities cut CymaBay Therapeutics from a “strong-buy” rating to an “outperform” rating in a research note on Friday, August 11th. Finally, SunTrust Banks, Inc. initiated coverage on CymaBay Therapeutics in a research note on Friday, August 18th. They issued a “buy” rating and a $15.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. CymaBay Therapeutics presently has an average rating of “Buy” and an average price target of $14.00.
ILLEGAL ACTIVITY WARNING: “CymaBay Therapeutics (CBAY) Getting Somewhat Positive Press Coverage, Accern Reports” was originally published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://www.chaffeybreeze.com/2017/11/13/cymabay-therapeutics-cbay-getting-somewhat-positive-press-coverage-accern-reports.html.
In other news, Director Kurt Von Emster sold 108,876 shares of the stock in a transaction on Tuesday, October 3rd. The stock was sold at an average price of $7.85, for a total transaction of $854,676.60. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Charles Mcwherter bought 5,000 shares of CymaBay Therapeutics stock in a transaction dated Thursday, November 2nd. The shares were bought at an average cost of $8.67 per share, for a total transaction of $43,350.00. Following the completion of the acquisition, the senior vice president now owns 10,300 shares in the company, valued at approximately $89,301. The disclosure for this purchase can be found here. Insiders have sold a total of 397,209 shares of company stock worth $3,267,417 in the last quarter. Company insiders own 15.10% of the company’s stock.
CymaBay Therapeutics Company Profile
CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.
Receive News & Ratings for CymaBay Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.